Item 2.02 Results of Operations and Financial Condition.

On May 12, 2022, Core Scientific, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

On May 12, 2022, the Company also released a corporate presentation reporting such results. A copy of the presentation is furnished hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders (the "Annual Meeting") on May 11, 2022. The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2022.

Proposal No. 1: Election of six nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. All nominees were elected. The votes were cast as follows:



                                            Votes           Broker
Name                     Votes For        Withheld        Non-Votes
Michael Levitt           133,296,383         321,963       86,104,769
Darin Feinstein          132,569,553       1,048,793       86,104,769
Jarvis Hollingsworth     133,297,002         321,344       86,104,769
Matt Minnis              133,311,166         307,180       86,104,769
Stacie Olivares          133,330,606         287,740       86,104,769
Kneeland Youngblood      133,083,408         534,938       86,104,769

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The votes were cast as follows:



                                                                       Votes
                                                      Votes For       Against       Abstained

Ratification of appointment of Ernst & Young LLP 216,297,134 78,796 3,347,185

Item 7.01 Regulation FD Disclosure.

The information contained in Item 2.02 is incorporated herein by reference.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits

Exhibit
  No.       Description

99.1          Press Release dated May 12, 2022.

99.2          Company Presentation dated May 12, 2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses